Novate Medical is developing next generation inferior vena cava (IVC) filters designed to reduce the likelihood of pulmonary embolism (PE) in high-risk clinical situations. The filters do not require retrieval, and solve many of the problems associated with current devices.

PE affects millions of patients worldwide and hundreds of thousands could potentially benefit from this filter technology.

ACT Venture Capital was the lead Early Stage investor in Novate and participated in multiple funding rounds with co-investment partners Seroba Life Sciences and Omnes Capital.